As of today (2024-06-11), PT Indofarma Tbk's share price is Rp153.00.
PT Indofarma Tbk's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2023 was Rp-80.89. Hence, PT Indofarma Tbk's Price-to-Free-Cash-Flow Ratio for today is N/A.
The historical rank and industry rank for PT Indofarma Tbk's Price-to-Free-Cash-Flow or its related term are showing as below:
During the past 13 years, PT Indofarma Tbk's highest Price-to-Free-Cash-Flow Ratio was 6025.00. The lowest was 4.38. And the median was 131.11.
ISX:INAF's Price-to-Free-Cash-Flow is not ranked *
in the Drug Manufacturers industry.
Industry Median: 22.78 * Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
During the past 12 months, the average Free Cash Flow per Share Growth Rate of PT Indofarma Tbk was -1847.40% per year.
During the past 13 years, PT Indofarma Tbk's highest 3-Year average Free Cash Flow per Share Growth Rate was 60.80% per year. The lowest was -46.70% per year. And the median was -28.40% per year.
PT Indofarma Tbk Price-to-Free-Cash-Flow Historical Data
The historical data trend for PT Indofarma Tbk's Price-to-Free-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of PT Indofarma Tbk's Price-to-Free-Cash-Flow
For the Drug Manufacturers - Specialty & Generic subindustry, PT Indofarma Tbk's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Indofarma Tbk's Price-to-Free-Cash-Flow Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PT Indofarma Tbk's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where PT Indofarma Tbk's Price-to-Free-Cash-Flow falls into.
PT Indofarma Tbk's Share Price of today is Rp153.00. PT Indofarma Tbk's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp-80.89.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
PT Indofarma Tbk Price-to-Free-Cash-Flow Related Terms
Thank you for viewing the detailed overview of PT Indofarma Tbk's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
PT Indofarma Tbk is a specialty and generic drug manufacturing company. The company has four business segments - Medicine, Medical Devices and others, Pharmaceutical Engineering, and Aliansi Strategis Segment. The Medicine business segment includes drug production, marketing and distribution and sales. The Medical Device Segment includes medical devices and other products. The Pharmaceutical Engineering Segment includes the sale and maintenance of packaging machines for the pharmaceutical industry to external parties.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ISX:INAF has been successfully added to your 